Article
Neurosciences
Shaunik Sharma, Steven Carlson, Adriana Gregory-Flores, Andy Hinojo-Perez, Ashley Olson, Thimmasettappa Thippeswamy
Summary: The study demonstrated that the Fyn/Src tyrosine kinase inhibitor SAR had a significant disease-modifying effect in the rat TLE model, reducing seizures and epileptiform spikes while modulating neuroinflammation and oxidative stress response.
NEUROBIOLOGY OF DISEASE
(2021)
Article
Cell Biology
Ling-Yen Chiu, I-Lun Hsin, Jen-Ning Tsai, Chih-Jung Chen, Chu-Chyn Ou, Wen-Jun Wu, Gwo-Tarng Sheu, Jiunn-Liang Ko
Summary: The combination treatment of Saracatinib and GMI showed synergistic and additive cytotoxic effects on A549 and A400 cells, inducing caspase-7 activation in A549 cells. The study suggests a novel strategy for treating lung cancer, with or without drug resistance, using a combination of GMI and Saracatinib.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Tingting Liang, Lu Lu, Xueting Song, Jianguo Qi, Jianhong Wang
Summary: This article reviews the combinations of microtubule targeting agents (MTAs) with other anticancer drugs to overcome toxicities, resistance, and improve treatment efficacy for cancer. It provides helpful information for combination therapy based on MTAs.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Article
Biochemistry & Molecular Biology
Busra Dincer, Gizem Yildiztekin, Irfan Cinar
Summary: This study investigates the potential of combining agomelatine (AGO), a synthetic melatoninergic drug, with paclitaxel (PTX) for the treatment of breast cancer. The results show that AGO has cytotoxic effects on breast cancer cells similar to melatonin (MTN), and combining AGO and MTN with PTX shows synergistic effects. The study also reveals differences in molecular mechanisms and the importance of MTN receptors in breast cancer cell types.
CHEMISTRY & BIODIVERSITY
(2023)
Article
Multidisciplinary Sciences
Kuei-Yen Tsai, Po-Li Wei, Mohamed Azarkan, Nasiha M'Rabet, Precious Takondwa Makondi, Hsin-An Chen, Chien-Yu Huang, Yu-Jia Chang
Summary: This study found that F3 bromelain can inhibit the proliferation of colorectal cancer cells, and has comparable cytotoxicity to unfractionated bromelain. F3 bromelain can also be used in combination with routine chemotherapeutic agents to increase cytotoxicity in colorectal cancer cells.
Article
Biochemistry & Molecular Biology
Yurika Nakagawa-Saito, Yuta Mitobe, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Chifumi Kitanaka, Masashi Okada
Summary: The deregulation of the FOXM1 transcription factor is a key change in ovarian cancer, and it contributes to the development and progression of the disease. A study investigated the effects of domatinostat, a HDAC inhibitor, on the expression of FOXM1 and the viability of ovarian cancer cells. Domatinostat was found to reduce the expression of FOXM1 and survivin, as well as the cell viability alone or in combination with other chemotherapeutic agents. These findings suggest that domatinostat may be a promising option for the treatment of ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Mingzhu Li, Lina Duan, Wenjie Wu, Wenjing Li, Lili Zhao, Ang Li, Xuebo Lu, Xinyu He, Zigang Dong, Kangdong Liu, Yanan Jiang
Summary: Gastric cancer is a leading cause of cancer-related deaths worldwide, and effective chemopreventive drugs are urgently needed. In this study, vortioxetine hydrobromide, an FDA-approved drug, is found to be a dual JAK2/SRC inhibitor and shows inhibitory effects on gastric cancer cell proliferation. This drug binds directly to JAK2 and SRC kinases, suppressing their activities and subsequently inhibiting the growth of gastric cancer. These findings suggest that vortioxetine hydrobromide has potential in the chemoprevention of gastric cancer.
Article
Chemistry, Organic
Ester Colarusso, Erica Gazzillo, Eleonora Boccia, Assunta Giordano, Maria Giovanna Chini, Giuseppe Bifulco, Gianluigi Lauro
Summary: Novel 6-methylquinazolin-4(3H)-one-based compounds were identified and synthesized as binders of the BRD9 epigenetic reader. Molecular docking experiments led to the selection of 16 compounds with good yields and binding potency toward BRD9, with compounds 14, 16, 18, 22, and 26 showing the highest activity.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
(2022)
Article
Oncology
Yitian Lang, Yan Lin, Dan Li, Jiyong Liu, Xiaoyan Liu
Summary: This study evaluated the cost-effectiveness of pembrolizumab for advanced gastric cancer from the perspective of the United States and China. The results showed that pembrolizumab plus chemotherapy or pembrolizumab monotherapy is not a cost-effective strategy for CPS=1 patients, but it is a cost-effective option for CPS=10 patients in the American setting.
Article
Oncology
Jill P. Smith, Hong Cao, Wenqiang Chen, Kanwal Mahmood, Teresa Phillips, Lynda Sutton, Allen Cato
Summary: Clinical studies have shown that immune checkpoint antibody therapy is effective for advanced gastric cancer patients, while the gastrin peptide can stimulate tumor growth through the CCK-BR receptor. In experimental models, a vaccine targeting the gastrin peptide (PAS) was able to inhibit tumor growth significantly.
FRONTIERS IN ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Rajashri R. Naik, Ashok K. Shakya, Safwan M. Aladwan, Mohamed El-Tanani
Summary: The coronavirus is rapidly spreading worldwide, and viral management aims to disrupt the virus's life cycle, minimize lung damage, and alleviate severe symptoms. Various strategies have been implemented, including repurposing FDA-approved kinase inhibitors that have shown antiviral activity against multiple viruses, including those associated with COVID-19.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Dan Liu, Furong Kou, Jifang Gong, Zhiqiang Wang, Xiaotian Zhang, Jian Li, Yan Li, Jie Li, Jun Zhou, Ming Lu, Xicheng Wang, Zhihao Lu, Yanshuo Cao, Jianjun Zou, Xiaoyu Zhu, Ruihua Xu, Lin Shen
Summary: This study aimed to evaluate the use of pyrotinib in the treatment of pretreated HER2-positive gastric cancer patients, and the results showed acceptable toxicities for both pyrotinib alone and in combination with docetaxel.
Article
Cell Biology
Pan-Quan Luo, Li-Xiang Zhang, Zhang-Ming Chen, Gang Wang, Hai Zhu, Songcheng Ying, Zhi-Jian Wei, Wen-Xiu Han, A-Man Xu
Summary: The combination of natural product cryptotanshinone (CTS) and anti-cancer drug trifluorothymidine (FTD) has a synergistic anti-gastric cancer effect, as shown by in vitro and in vivo experiments. FTD and CTS individually inhibit the growth of gastric cancer cells, and their combination enhances this inhibitory effect. The combination treatment achieves cell cycle arrest and increased apoptosis through different mechanisms. Moreover, the combination of CTS with another anti-cancer drug, TAS-102, also shows significant tumor growth inhibition in a mouse model. Therefore, the combination therapy of FTD and CTS holds promise as an effective treatment option for advanced gastric cancer.
Article
Integrative & Complementary Medicine
Naqibullah Norouzi, Fahimeh Alizadeh, Alireza Khodavandi, Mohammad Jahangiri
Summary: The study demonstrates that menthol alone or in combination with conventional antifungal agents can effectively combat Candida albicans infections and reduce biofilm formation.
JOURNAL OF HERBAL MEDICINE
(2021)
Article
Chemistry, Medicinal
Joana Moreira, Joana Almeida, Joana B. Loureiro, Helena Ramos, Andreia Palmeira, Madalena M. Pinto, Lucilia Saraiva, Honorina Cidade
Summary: In silico studies identified potential new MDM2/X ligands, which were synthesized and evaluated for their antiproliferative activity in cancer cells. A potential dual inhibitor was discovered, with antiproliferative effects associated with cell cycle arrest, apoptosis, and increased p53 and its targets.
Article
Oncology
Charles S. Fuchs, Mustafa Ozguroglu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandala, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesinski, Christian Caglevic, Hyun C. Chung, Kei Muro, Eric Van Cutsem, Anneli Elme, Peter Thuss-Patience, Ian Chau, Atsushi Ohtsu, Pooja Bhagia, Anran Wang, Chie-Schin Shih, Kohei Shitara
Summary: In this long-term analysis, second-line pembrolizumab did not significantly improve overall survival but was associated with higher 24-month OS rates than paclitaxel in the CPS>=1 population. Pembrolizumab also increased overall survival benefit with PD-L1 enrichment among patients with PD-L1-positive gastric/GEJ cancer and led to fewer treatment-related adverse events (TRAEs) compared to paclitaxel.
Meeting Abstract
Oncology
Manish A. Shah, Jaffer A. Ajani, Salah-Eddin Al-Batran, Yung-Jue Bang, Daniel V. T. Catenacci, Peter C. Enzinger, David H. Ilson, Sunnie S. Kim, Florian Lordick, Kohei Shitara, Eric Van Cutsem, Ahsan Arozullah, Jeffrey J. Raizer, Jung Wook Park, Rui-hua Xu
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Deirdre Jill Cohen, Josep Tabernero, Eric Van Cutsem, Yelena Y. Janjigian, Yung-Jue Bang, Shukui Qin, Zev A. Wainberg, Anran Wang, Natalyn Nicole Hawk, Chie-Schin Shih, Pooja Bhagia, Kohei Shitara
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Manish A. Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L. Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M. Brooks, Bo Xu, Wei Li, Chiang J. Li, Laura Borodyansky, Eric Van Cutsem
Summary: Adding napabucasin to paclitaxel did not improve survival in patients with second-line advanced gastric or gastroesophageal junction adenocarcinoma. The safety profile of napabucasin was driven by manageable gastrointestinal events, with grade >= 3 diarrhea occurring at a higher frequency with napabucasin plus paclitaxel versus placebo plus paclitaxel.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sehhoon Park, Chan-Young Ock, Hyojin Kim, Sergio Pereira, Seonwook Park, Minuk Ma, Sangjoon Choi, Seokhwi Kim, Seunghwan Shin, Brian Jaehong Aum, Kyunghyun Paeng, Donggeun Yoo, Hongui Cha, Sunyoung Park, Koung Jin Suh, Hyun Ae Jung, Se Hyun Kim, Yu Jung Kim, Jong-Mu Sun, Jin-Haeng Chung, Jin Seok Ahn, Myung-Ju Ahn, Jong Seok Lee, Keunchil Park, Sang Yong Song, Yung-Jue Bang, Yoon-La Choi, Tony S. Mok, Se-Hoon Lee
Summary: This study developed an AI-powered WSI analyzer of tumor-infiltrating lymphocytes (TIL) to predict the effectiveness of immune checkpoint inhibitors (ICI). The results showed that the inflamed immune phenotype (IP) correlated with enrichment in local immune cytolytic activity, higher response rate, and prolonged progression-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Joseph Chao, Zev A. Wainberg, Z. Alexander Cao, Deepti Aurora-Garg, Julie Kobie, Razvan Cristescu, Pooja Bhagia, Sukrut Shah, Josep Tabernero, Kohei Shitara, Lucjan Wyrwicz
Summary: This analysis of KEYNOTE-062 suggests an association between tumor mutational burden (TMB) and clinical efficacy with first-line pembrolizumab-based therapy in patients with advanced gastric/gastroesophageal junction adenocarcinoma. However, the clinical utility of TMB was attenuated after excluding patients with MSI-H tumors.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Tae Won Kim, Howard A. Burris, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
Summary: This study evaluated the first-in-human use of MOXR0916, a humanized monoclonal antibody, in the treatment of advanced solid tumors. The results showed that MOXR0916 was well tolerated and demonstrated evidence of tumor immune activation. Although objective responses were rare with monotherapy, further investigation in combination with PD-1/PD-L1 antagonists is warranted.
CLINICAL CANCER RESEARCH
(2022)
Meeting Abstract
Oncology
A. Italiano, A. Gazzah, J. Tabernero, Y-K. Kang, E. Calvo, M. Provencio Pulla, Y-J. Bang, F. Barlesi, P. L. Bedard, J. O. Park, J-S. Kim, M. Chadjaa, S. Yoruk, J-P. Delord
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun-Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
Summary: This study aimed to investigate the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-low gastric or gastroesophageal junction adenocarcinoma. The results showed that T-DXd has clinical activity in heavily pretreated patients with HER2-low gastric/GEJ adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M. Sjoquist, Andrew J. Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J. O'Callaghan, Niall C. Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, John Zalcberg, Timothy Price, John Simes, David Goldstein
Summary: This study aims to evaluate the efficacy and safety of regorafenib alone and in combination with nivolumab in advanced gastro-oesophageal cancer patients. The study consists of two international randomized controlled trials, comparing the efficacy of regorafenib versus placebo, and the efficacy of regorafenib plus nivolumab versus chemotherapy. The primary endpoint of the study is overall survival.
Article
Medicine, General & Internal
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.
Article
Biochemistry & Molecular Biology
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Summary: This study is a phase 2 basket trial evaluating the efficacy and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutated advanced rare cancers. The overall response rates in different tumor types ranged from 56% to 89%. Secondary endpoints included duration of response, progression-free survival, overall survival, and safety.
Article
Oncology
Fortunato Ciardiello, Yung-Jue Bang, Andres Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean-Philippe Metges, Antonio Sanchez Ruiz, Mariona Calvo, Andrew H. Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Zhaoyin Zhu, Neal Gupta, Robert J. Pelham, Lin Shen
Summary: The study investigated the efficacy and safety of maintenance therapy with Pamiparib in gastric cancer. The results showed that Pamiparib did not demonstrate a significant superiority in progression-free survival (PFS) compared to placebo, but it was well tolerated with few adverse events.
Article
Biochemistry & Molecular Biology
Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu
Summary: The GLOW trial demonstrated that zolbetuximab, a monoclonal antibody targeting CLDN18.2, combined with CAPOX, significantly improved progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.